Monitor for regulatory certification in South Korea and subsequent revenue contribution. The partnership is one of several market entries in 2026, but without disclosed financial terms, the near-term financial impact is unclear.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $0.1073entry
- T+1 · 4d ago −15.66%α −15.29% · $0.0905
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Baird Medical entered a strategic distribution partnership with ALLIS MED for exclusive distribution of its microwave ablation products in South Korea, pending regulatory certification. The deal expands the company's Asian footprint but has no stated financial terms and is contingent on regulatory approval.
Key Facts
- ALLIS MED will serve as Korea License Holder and manage regulatory submissions to the Ministry of Food and Drug Safety.
- ALLIS MED will become exclusive distributor of Baird Medical's products in South Korea after product certification.
- Baird Medical has entered multiple new markets in 2026 including Argentina, Egypt, Pakistan and Vietnam.
- The company has submitted FDA 510(k) and CE applications for its Irreversible Electroporation System.
- No financial terms of the partnership were disclosed.
Financial Impact
No financial terms disclosed; deal value not stated.
Risk Factors
- Regulatory approval in South Korea is required before distribution can begin; delays or denial would limit the deal's value.
- No financial terms disclosed, making it impossible to assess materiality.
- Company has a very small market cap ($4M), so even modest revenue from this deal could be significant, but uncertainty is high.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3401492 |
Track record
9 reports on BDMD
2 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +91.10% at T+60 after the Aug 18, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bearish 6/10 Entry $0.0910 Now $0.1070 −17.58% settles Dec 16
- Nov 12, 20264d ago Press Release Neutral 3/10 Viewing Entry $0.1073 Now $0.1070 −0.28% settles Dec 11
- Nov 5, 202611d ago 6-K Bearish 6/10 Entry $0.1575 Now $0.1070 +32.06% settles Dec 4
- Nov 4, 202612d ago Press Release Bearish 6/10 Entry $0.1575 Now $0.1070 +32.06% settles Dec 4
- Sep 30, 20266w ago 6-K Bearish 6/10 Entry $0.7440 to $0.1833 Now $0.1070 +85.62% ▲ +75.36% +76.07% vs SPY
- Sep 30, 20266w ago 6-K Mixed 6/10 Entry $0.7800 to $0.2820 Now $0.1070 −86.28% ▼ −63.85% −65.12% vs SPY
- Sep 3, 202610w ago 6-K Bullish 6/10 Entry $1.17 to $0.7511 Now $0.1070 −90.85% ▼ −35.80% −34.62% vs SPY
- Sep 3, 202610w ago Press Release Bullish 6/10 Entry $1.17 to $0.7511 Now $0.1070 −90.85% ▼ −35.80% −34.62% vs SPY
- Aug 18, 202613w ago EFFECT Bearish 6/10 Entry $1.09 to $1.06 Now $0.1070 +90.18% ▲ +2.75% +1.76% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers